EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Economic Profit
| 12 months ended: | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | |
|---|---|---|---|---|---|---|
| Net operating profit after taxes (NOPAT)1 | ||||||
| Cost of capital2 | ||||||
| Invested capital3 | ||||||
| Economic profit4 | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= – × =
The analysis of economic value creation from 2021 to 2025 reveals a significant contraction in economic profit, primarily driven by a substantial decline in net operating profit after taxes (NOPAT) occurring alongside a general increase in invested capital.
- Net Operating Profit After Taxes (NOPAT)
- A sharp downward trend is observed between 2021 and 2023, with NOPAT falling from 7.82 billion to 2.82 billion. While a partial recovery occurred in 2024, operational profits remained significantly below 2021 levels, ending 2025 at 3.15 billion.
- Invested Capital and Cost of Capital
- Invested capital demonstrated a gradual upward trajectory, increasing from 10.79 billion in 2021 to 13.20 billion by 2025. During this same period, the cost of capital remained remarkably stable, fluctuating narrowly between 9.88% and 10.04%, indicating a constant hurdle rate for value creation.
- Economic Profit Performance
- Economic profit experienced a precipitous decline, dropping from 6.75 billion in 2021 to a period low of 1.62 billion in 2023. Although economic profit recovered to 2.11 billion in 2024, it retracted to 1.83 billion in 2025. The persistence of positive figures indicates that the entity continues to generate returns exceeding its cost of capital, although the magnitude of this excess value has diminished significantly.
The divergence between increasing invested capital and decreased NOPAT suggests a reduction in capital efficiency over the analyzed period. The overall compression of economic profit reflects a lower margin of excess return over the required cost of capital compared to the performance peak observed in 2021.
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in deferred revenue.
3 Addition of increase (decrease) in equity equivalents to net income.
4 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =
5 2025 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =
6 Addition of after taxes interest expense to net income.
7 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =
8 Elimination of after taxes investment income.
The financial performance, as indicated by Net Income and Net Operating Profit After Taxes (NOPAT), demonstrates considerable fluctuation over the five-year period. A significant decline in both metrics is observed between 2021 and 2023, followed by a partial recovery in subsequent years.
- NOPAT Trend
- NOPAT experienced a substantial decrease from US$7,819,887 thousand in 2021 to US$2,823,336 thousand in 2023, representing a decline of approximately 64%. This suggests a weakening in core operational profitability. A subsequent increase to US$3,374,924 thousand in 2024 indicates some recovery, but NOPAT decreased again in 2025 to US$3,147,470 thousand, suggesting the recovery may not be sustained.
- Relationship between Net Income and NOPAT
- While both Net Income and NOPAT follow a similar pattern of decline and partial recovery, NOPAT consistently represents a larger value than Net Income. This difference could be attributed to factors not reflected in net income, such as non-operating expenses or gains, or differences in accounting treatment. The gap between the two metrics appears relatively stable throughout the period.
The observed volatility in NOPAT warrants further investigation to determine the underlying drivers. Potential areas of inquiry include changes in revenue, cost of goods sold, operating expenses, and tax rates. The decrease in 2025, following the 2024 increase, suggests potential challenges in maintaining operational efficiency or market position.
- Overall Performance
- The period under review demonstrates a period of instability. While the company shows some ability to recover from the low point in 2023, the performance in 2025 indicates that the recovery may be limited. Continued monitoring of NOPAT and its contributing factors is recommended.
Cash Operating Taxes
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The relationship between income tax expense and cash operating taxes demonstrates notable fluctuations over the five-year period. Cash operating taxes generally exceed income tax expense, suggesting timing differences between reported accounting income and actual cash outflows for taxes.
- Overall Trend - Cash Operating Taxes
- Cash operating taxes exhibit a decreasing trend from 2021 to 2023, followed by a slight increase in 2024 and a more substantial rise in 2025. The value decreased from US$1,400,760 thousand in 2021 to US$995,682 thousand in 2023, representing a 28.9% decline. A modest increase to US$989,515 thousand occurred in 2024, before a significant jump to US$1,372,884 thousand in 2025.
- Overall Trend - Income Tax Expense
- Income tax expense shows a significant decrease from 2021 to 2022, followed by continued declines through 2023, a slight increase in 2024, and a further increase in 2025. The value fell from US$1,250,500 thousand in 2021 to US$245,700 thousand in 2023, a decrease of 80.3%. An increase to US$367,300 thousand was observed in 2024, and a further increase to US$725,800 thousand in 2025.
- Relationship Between Tax Items
- The difference between cash operating taxes and income tax expense varied considerably. In 2021, cash operating taxes exceeded income tax expense by US$150,260 thousand. This difference narrowed in 2022 to US$725,998 thousand. By 2023, cash operating taxes exceeded income tax expense by US$750,000 thousand. The difference decreased to US$622,115 thousand in 2024, and then increased to US$647,084 thousand in 2025. This suggests that deferred tax assets or liabilities are playing a significant role in the company’s tax position.
The substantial fluctuations in both income tax expense and cash operating taxes warrant further investigation to understand the underlying drivers, such as changes in tax laws, the utilization of tax credits, or alterations in the company’s accounting practices related to deferred taxes. The increasing trend in both measures in 2025 suggests a potential increase in future tax liabilities.
Invested Capital
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of deferred revenue.
4 Addition of equity equivalents to stockholders’ equity.
5 Removal of accumulated other comprehensive income.
6 Subtraction of construction in progress.
7 Subtraction of marketable securities.
The invested capital of the organization demonstrates a generally increasing trend over the five-year period, although with some fluctuation. Total reported debt & leases and stockholders’ equity both contribute to this figure, and their individual movements influence the overall invested capital.
- Invested Capital Trend
- Invested capital increased from US$10,786,500 thousand in 2021 to US$12,287,700 thousand in 2022, representing a substantial rise. A decrease was then observed in 2023, with invested capital falling to US$11,998,500 thousand. Subsequent years show renewed growth, reaching US$12,653,600 thousand in 2024 and US$13,198,700 thousand in 2025. This suggests periods of capital investment followed by potential adjustments or reallocations.
- Debt & Leases
- Total reported debt & leases exhibits a consistent, albeit moderate, upward trend throughout the period. Starting at US$2,767,900 thousand in 2021, it increases to US$2,972,700 thousand in 2025. The increases are relatively steady year-over-year, indicating a consistent reliance on debt financing.
- Stockholders’ Equity
- Stockholders’ equity demonstrates a strong and consistent upward trend. It increased significantly from US$18,768,800 thousand in 2021 to US$31,256,900 thousand in 2025. This growth suggests successful earnings retention and/or new equity issuance, contributing significantly to the overall increase in invested capital.
- Relationship between Components
- While both debt & leases and stockholders’ equity contribute to invested capital, stockholders’ equity represents the larger portion and drives the majority of the overall trend. The relatively smaller increases in debt & leases are overshadowed by the substantial growth in equity. The dip in invested capital in 2023 appears to be influenced by a combination of factors, including a slight decrease in equity growth and the impact of debt levels.
In summary, the organization’s invested capital has generally increased over the observed period, primarily driven by growth in stockholders’ equity. Debt & leases have also increased, but to a lesser extent. The fluctuation in invested capital in 2023 warrants further investigation to understand the underlying causes.
Cost of Capital
Regeneron Pharmaceuticals Inc., cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2025-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2024-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | ÷ | = | × | = | |||||||||
| Long-term debt and finance lease liabilities3 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Operating lease liability4 | ÷ | = | × | × (1 – 21.00%) | = | ||||||||
| Total: | |||||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in thousands
2 Equity. See details »
3 Long-term debt and finance lease liabilities. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| Economic spread ratio3 | ||||||
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The financial performance over the analyzed five-year period reflects a significant contraction in value creation efficiency, characterized by a substantial decrease in economic profit despite a general expansion of the invested capital base.
- Economic Profit Trends
- A sharp decline in economic profit is observed between 2021 and 2023, falling from US$ 6,753,672 thousand to US$ 1,619,119 thousand. While a partial recovery occurred in 2024, reaching US$ 2,112,396 thousand, the figure retracted to US$ 1,831,166 thousand by 2025. This trajectory indicates a marked reduction in the company's ability to generate returns above its cost of capital compared to the 2021 peak.
- Invested Capital Growth
- Invested capital demonstrated a general upward trend, increasing from US$ 10,786,500 thousand in 2021 to US$ 13,198,700 thousand in 2025. A marginal contraction occurred in 2023, but the overall trajectory suggests a consistent commitment of resources into the business operations over the period.
- Economic Spread Ratio Analysis
- The economic spread ratio experienced a dramatic compression, dropping from 62.61% in 2021 to 18.86% in 2022. The ratio reached its lowest point in 2023 at 13.49% before stabilizing between 13.87% and 16.69% in the subsequent two years. This trend reveals a significant narrowing of the gap between the return on invested capital and the weighted average cost of capital, signifying a decrease in the efficiency of capital deployment.
The correlation between rising invested capital and falling economic profit resulted in the precipitous decline of the economic spread ratio. The data suggests that while the capital base has grown by approximately 22% since 2021, the economic profit has decreased by nearly 73%, indicating that new capital investments have not yielded the same level of value addition as previous allocations.
Economic Profit Margin
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Economic profit1 | ||||||
| Revenues | ||||||
| Add: Increase (decrease) in deferred revenue | ||||||
| Adjusted revenues | ||||||
| Performance Ratio | ||||||
| Economic profit margin2 | ||||||
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =
3 Click competitor name to see calculations.
The financial performance between 2021 and 2025 is characterized by a significant contraction in economic value generation, followed by a period of relative stabilization at lower levels. A sharp decline in both absolute economic profit and the economic profit margin occurred early in the period, with subsequent years failing to return to 2021 peaks despite some recovery in adjusted revenues.
- Economic Profit Trajectory
- Economic profit experienced a severe reduction from a peak of 6,753,672 thousand USD in 2021 to a low of 1,619,119 thousand USD in 2023. While a moderate recovery was noted in 2024, reaching 2,112,396 thousand USD, the figure declined again to 1,831,166 thousand USD by 2025, indicating a failure to sustain an upward growth trend in value creation.
- Adjusted Revenue Analysis
- Adjusted revenues showed significant volatility, dropping from 15,951,500 thousand USD in 2021 to 12,205,300 thousand USD in 2022. A gradual recovery trend was observed through 2024, where revenues climbed back to 14,429,800 thousand USD, before slightly receding to 14,291,200 thousand USD in 2025. The revenue recovery did not mirror the scale of the initial 2021 performance.
- Economic Profit Margin Compression
- The economic profit margin underwent a drastic compression, falling from 42.34% in 2021 to 12.31% in 2023. This represents a substantial erosion of the company's ability to generate economic profit relative to its adjusted revenues. The margin remained suppressed in the final two years, fluctuating between 14.64% in 2024 and 12.81% in 2025, suggesting a structural shift in the efficiency of capital utilization or an increase in the cost of capital relative to operating returns.
The correlation between the decline in adjusted revenues and the collapse of the economic profit margin suggests that the reduction in value creation was more aggressive than the reduction in top-line revenue. The fact that the margin remained low despite the partial recovery of revenues in 2024 indicates that the factors driving the initial decline had a lasting impact on the economic efficiency of the business model.